Enzo Life Sciences Exendin-4 GLP-1 receptor agonist
Exendin-4 is a 39 aa polypeptide and incretin mimetic which was first isolated from Gila monster saliva. The synthetic form, Exenatide, is a glucagon like peptide-1 (GLP-1) agonist approved for the treatment of diabetes mellitus type II.
Research shows Exendin-4 is involved in glucose-dependent enhancement of insulin secretion, reduction of hyperglycemia, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying and reduction of food intake, often with body weight reduction or blunting of weight gain.
Phone: 02 4575 0309
HAWK Biosystems Quantifying Functions in Proteins (QF-Pro) reagent kits
HAWK Biosystems' Quantifying Functions in Proteins (QF-Pro) reagent kits contain the tailored...
Amsbio validated cytokines for organoid culture
Amsbio has launched over a range of over 30 independently developed and manufactured organoid...
Dendritics monoclonal antibodies for dendritic cell research
Dendritics' mouse and rat antibodies are logically grouped into several product families: DC...
Learn More
I am interested in Enzo Life Sciences Exendin-4 GLP-1 receptor agonist.
Complete the form and a supplier representative will be in touch.
